Skip to main content
. Author manuscript; available in PMC: 2014 Aug 14.
Published in final edited form as: Cancer. 2012 May 8;118(22):5614–5622. doi: 10.1002/cncr.27593

Table 1.

Comparison of Patient Characteristics for those in NSABP trial C-07 and the Cross-sectional and Longitudinal LTS-01 Samples

Characteristic C-07 LTS-01
Cross-Sectional Sample Longitudinal Sample

No. of Patients (%) No. of Patients (%) P* No. of Patients (%) P*
N 2467 353 92
Age, years
< 50 561 (22.7) 79 (22.4) 0.46 20 (21.7) 0.53
50-59 712 (28.9) 110 (31.2) 32 (34.8)
60-69 794 (32.2) 117 (33.1) 29 (31.5)
≥ 70 400 (16.2) 47 (13.3) 11 (12.0)
Sex
Male 1392 (56.4) 214 (60.6) 0.11 60 (65.2) 0.09
Female 1075 (43.6) 139 (39.4) 32 (34.8)
Positive Nodes
0 714 (28.9) 112 (31.7) 0.03 30 (32.6) 0.02
1-3 1121 (45.4) 172 (48.7) 50 (54.4)
4+ 631 (25.6) 69 (19.6) 12 (13.0)
Unknown 1 (<0.1) 0 (0) 0 (0)
Site
Left Colon 499 (20.2) 78 (22.1) 0.79 20 (21.7) 0.39
Right Colon 1085 (44.0) 150 (42.5) 46 (50.0)
Sigmoid 855 (34.7) 122 (34.6) 26 (28.3)
Multiple 28 (1.1) 3 (0.9) 0 (0)

Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel Project; LTS-01, Long-Term Survivors study; FULV, fluorouracil and leucovorin; FLOX, FULV plus oxaliplatin.

*

P-value from the χ2 goodness of fit test.

χ2 goodness of fit test does not include unknown category.